Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


DxS announces license agreement with Wellcome Trust to expand their range of companion diagnostics


Manchester, 2 September 2008, DxS, a personalised medicine company and leaders in the provision of companion diagnostics, has signed a non-exclusive global licensing agreement with the Wellcome Trust. DxS will provide a research test for use in clinical trials to detect the presence of the V600E B-RAF mutation, which is found in melanomas, lung and thyroid cancers.

The V600E B-RAF mutation was identified by scientists at the Wellcome Trust and can be found in around 36% to 40% of skin and thyroid cancers and up to 13% of cancers in the large intestine.

Researchers will use the test to determine a patient's cancer mutation status, which may predict how they respond to cancer therapies. If clinical trials are successful, this could lead to a companion diagnostics to predict response for novel cancer therapies for skin, thyroid and large intestine cancers.

Dr. Stephen Little, CEO of DxS Ltd., said: 'With many novel drugs in development for skin, thyroid and colon cancer the potential for this assay is enormous. Through this licensing agreement, we plan to expand the range of biomarker tests to our customers, aiding the treatment of a number of types of cancer.'

Glenn Wells, Business Development Manager at The Wellcome Trust added: 'We believe the identification of the B-RAF mutation could have considerable implications for the way in which treatment of melanomas, lung and thyroid cancers are handled, and are extremely pleased to have reached this agreement with DxS to allow further research and clinical trials to be undertaken with this assay.'

Using their real-time PCR technology Scorpions®, DxS has developed a highly sensitive and selective test able to detect mutations at very low levels, and can be performed in less than three hours.

This deal builds on news earlier this year, which saw DxS chosen to supply the K-RAS companion diagnostic for Amgen's colorectal cancer therapy, Vectibix, and a global distribution deal with Roche Diagnostics.

Financial details were not disclosed.

-ends-


For further information, please contact:

Sue Charles, Tony Stephenson, John McIntyre
College Hill Life Sciences
+44 (0)20 7866 7864
Tony.stephenson@collegehill.com


Notes to Editors

DxS is a personalised medicine company providing products, technology and services to the healthcare industry to enable the delivery of safe and effective medicines. The Company has also established itself as a leader in the provision of companion diagnostics to the personalised cancer medicine market.

DxS has a range of products including cancer mutation assays and kits, molecular diagnostic technologies and genetic analysis services. Its Therascreen® range of CE-marked kits can identify genetic tumour mutations affecting how patients respond to cancer therapies, enabling doctors and drug companies to provide the treatment most likely to benefit patients. DxS produce two clinical diagnostic kits, K-RAS, and EGFR-29. The K-RAS assay has been chosen as the companion diagnostic for Amgen's colorectal cancer therapy Vectibix®. DxS has an exclusive global distribution agreement with Roche Molecular Systems for the distribution of the TheraScreen K-RAS Mutation Test and TheraScreen EGFR 29 Mutation Test.

DxS' real-time PCR technology, Scorpions® utilises its speed and sensitivity and underpins the products and services. This class-leading technology is also available for licence to diagnostic companies, for research, applied and other applications.

DxS is a private, venture capital backed company operating from Manchester's Technology Quarter within the UK.

For further information please visit www.dxsdiagnostics.com

The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending around £600 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. http://www.wellcome.ac.uk


Publisher Contact Information:

College Hill Life Sciences
+44 (0)20 7866 7864
Tony.stephenson@collegehill.com

Company profile of DxS Ltd (acquired by Qiagen)
Past press releases of DxS Ltd (acquired by Qiagen).

Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.